Blood flow imaging solution gains FDA clearance

RFPi, a Greenville, North Carolina-based medical imaging company, announced that its iCertainty blood flow and perfusion imaging solution has received FDA clearance.

iCertainty allows surgeons to visualize patient blood flow and perfusion without interrupting the procedure. According to RFPi, it is the first solution that provides this perspective without requiring injections, dyes, radiation or another type of direct patient contact.

“Repeat surgery rates in iCertainty’s target indications run as high as 20 percent—a figure that masks a tremendous amount of patient discomfort, uncertainty and inconvenience, as well as financial loss for hospitals and insurers,” Jeffery Basham, RFPi CEO, said in a prepared statement. “iCertainty offers an entirely new and advanced standard of imaging detail, speed, ease and flexibility that should benefit surgeons, hospitals and third-party payers—and, most importantly, the patients they all care for.”

The company is currently securing Series B funding.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The new F-18 flurpiridaz radiotracer is expected to help drive cardiac PET growth, but it requires waiting between rest and stress scans. Software from MultiFunctional Imaging can help care teams combat that problem.

News of an incident is a stark reminder that healthcare workers and patients aren’t the only ones who need to be aware around MRI suites.

The ACR hopes these changes, including the addition of diagnostic performance feedback, will help reduce the number of patients with incidental nodules lost to follow-up each year.